CurrentCignaPolicy N/A

Hereditary Angioedema - Ruconest Drug Quantity Management Policy - Per Days

Defines Cigna's drug quantity limits, override rules, and coverage criteria for Ruconest (recombinant C1-INH) used to treat acute hereditary angioedema attacks for affected members and providers.

Policy Summary

PayerCigna

PolicyHereditary Angioedema - Ruconest Drug Quantity Management Policy - Per Days

Policy CodePolicy N/A

Change TypeQuantity override increasedclarifications to override calculation

Effective DateN/A

Next Review DateJan 29, 2025

Key ActionRequest a one-time 30-day override to approve 16 additional Ruconest vials when treating a subsequent HAE attack, calculated as prior vials received plus 16.

SourceLink

POLICY UPDATE CHANGES

Override quantity updated to approve a one-time override for 16 additional vials (previously 4 vials) when additional doses are required to treat a subsequent HAE attack.

Policy statement was updated to note that 'one-time' approvals are provided for 30 days in duration.

2,100units per single-use vial

16 vialsRetail max per 28 days

48 vialsHome delivery max per 84 days

50 U/kgrecommended dose (max)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

≤2 doses/24hdose frequency limit

Coverage Criteria and Drug Quantity Management

Drug quantity limits and override

Covered when ALL of the following are met:

Standard quantity limits: Retail maximum quantity: 16 vials per 28 days; Home delivery maximum quantity: 48 vials per 84 days.Retail=16/28 days; Home=48/84 days

Package size = 2,100 units per vial

Override for additional attacks: If the patient requires additional doses to treat a subsequent HAE attack, approve a one-time override for 16 additional vials at retail or home delivery.One override allowed once every 30 days

At retail, approval = vials received in past 28 days + 16; At home delivery, approval = vials received in past 84 days + 16; 'One-time' approvals are provided for 30 days in duration.

Any request for a quantity exception that goes beyond the established Drug Quantity Limits and the policy’s defined one-time override provision is considered not medically necessary.

Requests that exceed the Drug Quantity Management limits and do not meet the specified override criteria will be determined to be not medically necessary.

Dose and Administration Limits

Maximum dose per administration

Maximum dose per administration4,200 units (50 units/kg, do not exceed 4,200 units per dose)

Recommended dosing methodSlow intravenous injection over approximately five minutes

Repeat dosing guidanceIf symptoms persist, an additional dose may be administered at the recommended dose level (do not exceed 4,200 units)

Maximum doses per 24 hours

Maximum doses per 24 hoursNo more than 2 doses per 24 hours

Clinical trial noteSecond rescue dose was required for ~11% of treated patients; most responded to a single dose

Override Rules and Operational Notes for Providers

Prior Authorization

One-time override for additional vials

One-time approvals (overrides) are provided for 30 days in duration. One override may be approved once every 30 days to allow an additional 16 vials when a patient requires additional doses to treat a subsequent hereditary angioedema (HAE) attack. Quantities beyond the Drug Quantity Management limits require override documentation and will be reviewed per the policy criteria.

One-time override: Approve a one-time override for 16 additional vials at retail or home delivery when needed to treat a subsequent HAE attack.
Override frequency: ONE override may be approved ONCE every 30 days.
Documentation: Quantities beyond Drug Quantity Management limits require override documentation and will be adjudicated per policy criteria.

Billing Rule

Calculation of approval quantity for overrides

Permitted Quantities and Overrides

Ruconest (2,100 unit vial) — retail quantity limit

Package size2,100 unit single-dose vial

Retail quantity limit (vials per 28 days)16 vials per 28 days

Coverage stanceCovered as medically necessary when within defined quantity limits

Ruconest (2,100 unit vial) — home delivery

Home delivery quantity limit (vials per 84 days)48 vials per 84 days

Package size2,100 unit single-dose vial

Coverage channel note

Dispensing Channels and Calculations

Note

Site-of-care: retail and home delivery coverage and override calculation

Ruconest is covered for both retail dispensing and home delivery within the stated quantity limits; overrides are calculated differently by dispensing channel (retail = past 28 days +16; home delivery = past 84 days +16).

Retail maximum = 16 vials per 28 days
Home delivery maximum = 48 vials per 84 days
Overrides follow channel-specific look‑back periods when calculating approved quantity

Clinical Background

Hereditary angioedema (HAE) is characterized by recurrent acute, potentially severe attacks of angioedema. Ruconest is a recombinant C1 esterase inhibitor administered by intravenous infusion for the treatment of acute HAE attacks in eligible patients. Product packaging is a single‑use vial containing 2,100 units, and the policy defines specific quantity limits and management rules for retail and home delivery dispensing to ensure appropriate on‑demand access while limiting excess supply.

Key Definitions

Ruconest — Recombinant C1 esterase inhibitor

Drug class and formulationRecombinant C1 esterase inhibitor (C1-INH), intravenous infusion

IndicationTreatment of acute hereditary angioedema (HAE) attacks in adults and adolescents

Recommended dosing contextDosed at 50 units/kg up to a maximum of 4,200 units; administered as a slow IV injection; an additional dose may be given if symptoms persist

On-demand treatment — definition and guideline recommendation

Definition of on-demand treatmentTreatment administered at the onset of an acute HAE attack

Guideline recommendationGuidelines recommend that all patients with confirmed HAE have access to at least two standard doses of an approved on-demand medication

Policy Summary

PayerCigna

PolicyHereditary Angioedema - Ruconest Drug Quantity Management Policy - Per Days

Policy CodePolicy N/A

Change TypeQuantity override increasedclarifications to override calculation

Effective DateN/A

Next Review DateJan 29, 2025

Key ActionRequest a one-time 30-day override to approve 16 additional Ruconest vials when treating a subsequent HAE attack, calculated as prior vials received plus 16.

SourceLink

On This Page

Timing for rescue dosingRescue treatment given if no beginning of relief within 4 hours after first dose in trial

Calculate the approval quantity for an override by adding 16 vials to the number of Ruconest vials the patient has received within the applicable lookback period: 28 days for retail and 84 days for home delivery. Use the resulting total as the approved quantity for the 30-day override.

Retail calculation: Approval = vials received in past 28 days + 16 vials.
Home delivery calculation: Approval = vials received in past 84 days + 16 vials.

Denial Risk

Quantity management enforcement

If the Drug Quantity Management rule is not met at the point of service, coverage determination will follow the policy criteria. Providers must submit override requests with supporting documentation; quantities beyond the specified maximums require review and justification per the policy.

Enforcement: Coverage determinations follow the policy criteria when quantity limits are exceeded at point of service.
Required info: Submit documentation supporting medical necessity for overrides beyond limits.
Limits: Retail max = 16 vials per 28 days; Home delivery max = 48 vials per 84 days (unless a one-time override is approved as described).

Home delivery limits differ from retail and are enforced per policy

Override for additional vials

One-time override quantityApprove one-time override for 16 additional vials (vials), when needed to treat a subsequent HAE attack

Override frequency and durationONE override may be approved ONCE every 30 days; one-time approvals are provided for 30 days in duration

Calculation guidanceAt retail, approval = vials received in past 28 days + 16; At home delivery, approval = vials received in past 84 days + 16

Clinical rationaleOn-demand treatment is most effective when administered early after attack onset